New hope for Duchenne muscular dystrophy (DMD) patients? CRISPR cured a mouse — and humans could be next

Credit: Irvine/NIST
Credit: Irvine/NIST

DMD is a fatal — and currently incurable — genetic condition that causes the body’s muscles to deteriorate over time. 

The disease is always caused by errors in the gene for a muscle protein, called dystrophin. But for 10-15% of patients… the problem is caused by a duplication mutation, where part of the gene appears twice.

[Researcher Ronald] Cohn’s team injected [a model] mouse with a CRISPR molecule, designed to eliminate the mutation and (hopefully) restore the normal function of the gene.


The results were incredible.

Before and after pictures show a dramatic difference between the mouse’s muscle strength and condition. After the CRISPR treatment, signs of weakened muscles disappeared.

Not long ago, gene therapy became a promising treatment for Duchenne muscular dystrophy. But traditional gene therapy is a different process than gene editing. A gene therapy treatment works by injecting harmless, gene-carrying virus into the body to deliver a new, functional copy of a faulty gene. For DMD, that faulty gene is the dystrophin gene.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.


In the case of DMD caused by a duplication mutation, CRISPR can simply snip away the harmful duplicate gene, which is much simpler than delivering a new gene or replacing the old.

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend